Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Prof Andi Roy who was awarded a fellowship to further develop her independent research.

Prof Andi Roy (right) with colleagues Dr Beth Psaila and Dr Supat Thongjuea
Prof Andi Roy (right) with colleagues Dr Beth Psaila and Dr Supat Thongjuea

Prof Anindita Roy, Associate Professor in the Department of Paediatrics, has been awarded a Wellcome Clinical Research Career Development Fellowship to study the developmentally-regulated changes in haematopoiesis that lead to treatment-resistant childhood leukaemias. The project will specifically focus on infant Acute Lymphoblastic Leukaemia (iALL), a type of cancer with high relapse rates and poor survival. These types of cancer are characterised by a translocation in the MLL gene, which takes place in utero. Prof Roy will examine at the molecular level why human fetal cells are particularly susceptible to this type of leukaemic transformation and how it progresses, using both in vitro and in vivo models. The ultimate aim of the research is to develop new and effective treatments for this condition.

Similar stories

Innovation award for Paediatrics researcher to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Professor Matthew Snape named NIHR Senior Investigator

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Enriching Engagement (Round 2) awardees announced

The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.

Typhoid vaccine project wins Vice-Chancellor award

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!

Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK

A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.